8 results on '"Hyun, Hak-Jun"'
Search Results
2. Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach.
- Author
-
Choi, Min Joo, Na, Yewon, Hyun, Hak Jun, Nham, Eliel, Yoon, Jin Gu, Seong, Hye, Seo, Yu Bin, Choi, Won Suk, Song, Joon Young, Kim, Dong Wook, Kim, Young-Eun, Jung, Jaehun, and Cheong, Hee Jin
- Subjects
- *
VACCINE safety , *COVID-19 vaccines , *COVID-19 , *NATIONAL health insurance , *MESSENGER RNA , *COHORT analysis - Abstract
This nationwide cohort study compared the incidence of adverse events of special interest (AESIs) between adenoviral vector-based (ChAdOx1) and mRNA-based (BNT162b2 or mRNA-1273) coronavirus disease 2019 (COVID-19) vaccines. A targeted trial emulation study was conducted using data from the National Health Insurance Service database. Vaccinees aged 18–85 years who had received at least one dose of ChAdOx1 or an mRNA-based vaccine were identified. The 42-day risks of AESIs were calculated. A total of 1 767 539 ChAdOx1 vaccinees were matched exactly with mRNA vaccinees according to their risk factors. The 42-day risks of adverse events were low (∼0 to 176 events per 100 000 persons in both vaccine groups), and the incidence rates of AESIs were comparable between the two platforms, except for a higher occurrence of acute cardiac injury (incidence rate ratio [IRR], 1.22; 95% CI, 1.10–1.35), myocarditis or pericarditis (IRR, 2.14; 95% CI, 1.14–4.04), and arrhythmia (IRR, 1.46; 95% CI, 1.24–1.71) in mRNA vaccinees. The incidence of Guillain–Barré syndrome (IRR, 0.20; 95% CI, 0.06–0.69), vasovagal syncope (IRR, 0.77; 95% CI, 0.62–0.97), radiculopathy (IRR = 0.59, 95% CI, 0.41–0.84), and aseptic arthritis (IRR, 0.81; 95% CI, 0.70–0.93) was significantly lower in mRNA-based vaccinees compared with ChAdOx1 vaccinees. A remarkable platform-dependent difference was observed in the safety profiles of COVID-19 vaccines, particularly for myocarditis or pericarditis and Guillain–Barré syndrome. However, the overall risk of AESIs was low for both vaccine platforms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Comparison of the second and third waves of the COVID-19 pandemic in South Korea: Importance of early public health intervention.
- Author
-
Seong, Hye, Hyun, Hak Jun, Yun, Jin Gu, Noh, Ji Yun, Cheong, Hee Jin, Kim, Woo Joo, and Song, Joon Young
- Subjects
- *
COVID-19 pandemic , *COVID-19 , *SOCIAL advocacy , *PUBLIC health , *DEATH rate - Abstract
• Epidemiologic features of the second and third waves of the coronavirus disease 2019 (COVID-19) pandemic in South Korea were compared. • Strengthening of social distancing policies was delayed in the third wave compared with the second wave. • The third wave persisted longer than the second wave, and had a higher case fatality rate. • Early public health intervention is important to control the COVID-19 pandemic. To compare epidemiologic features of the second and third waves of the coronavirus disease 2019 (COVID-19) pandemic in South Korea. Nationwide COVID-19 data were collected between 6 May and 30 December 2020. The degree of social activity was estimated using an Internet search trend analysis program for leisure-related keywords, including 'eating-out', 'trip' and 'get directions' (transportation). Demographics, transmission chains, case fatality rates, social activity levels and public health responses were compared between the second (13 August–18 September 2020) and third (4 November 2020–present) waves. In comparison with the second wave, the third wave was characterized by delayed strengthening of social distancing policies (3 vs. 15 days), longer duration (36 vs. >56 days) and a higher case fatality rate (0.91% vs. 1.26%). There were significant differences in transmission chains between the second and third waves (P < 0.01). In comparison with the second wave, the proportion of local clusters (24.8% vs. 45.7%) was lower in the third wave, and personal contact transmission (38.5% vs. 25.9%) and unknown routes of transmission (23.5% vs. 20.8%) were higher in the third wave. Early and timely interventions with strengthened social distancing policies should be implemented to suppress and control the COVID-19 pandemic effectively. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Risk factors for SARS-CoV-2 transmission in non-household clusters.
- Author
-
Noh, Ji Yun, Song, Joon Young, Hyun, Hak Jun, Yoon, Jin Gu, Seong, Hye, Cheong, Hee Jin, Yoon, Soo-Young, Yang, Jeong-Sun, Lee, Joo-Yeon, and Kim, Woo Joo
- Abstract
• Face-to-face talking was the most important risk factor of SARS-CoV-2 transmission. • Persons aged ≥ 40 years had a higher risk of SARS-CoV-2 infection. • A crowded space and prolonged exposure may facilitate viral transmission. • 6.6% did not have any close contact with COVID-19 patients, suggesting potential airborne transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
- Author
-
Kim, Woo Joo, Roberts, Christine C., Song, Joon Young, Yoon, Jin Gu, Seong, Hye, Hyun, Hak-Jun, Lee, Hyojin, Gil, Areum, Oh, Yeeun, Park, Ji-Eun, Lee, Ji-Eun, Jeon, Bohyun, Kane, Deborah, Spruill, Susan, Kudchodkar, Sagar B., Muthumani, Kar, Park, Young K., Kwon, Ijoo, and Maslow, Joel N.
- Subjects
- *
DNA vaccines , *COVID-19 vaccines , *IMMUNE response , *MESSENGER RNA , *COMBINED vaccines , *IMMUNOGLOBULINS - Abstract
• Heterologous mRNA boost following GLS-5310 DNA vaccination was well tolerated. • Neutralizing antibody responses were enhanced 110 fold to GMT of 1244.8. • Binding antibody responses were enhanced 1,187-fold to GMT of 405,920. • Boosted antibody responses similar to other vaccine combinations. • Boosted T cell responses were many-fold higher than other vaccine combinations. Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112–120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.
- Author
-
Kim, Woo Joo, Roberts, Christine C., Song, Joon Young, Yoon, Jin Gu, Seong, Hye, Hyun, Hak-Jun, Lee, Hyojin, Gil, Areum, Oh, Yeeun, Park, Ji-eun, Jeon, Bohyun, Lee, Ji-Eun, Choi, Sang Kyu, Yoon, Sun Kyung, Lee, Sunhee, Kim, Byoungguk, Kane, Deborah, Spruill, Susan, Kudchodkar, Sagar B., and Muthumani, Kar
- Subjects
- *
DNA vaccines , *MONONUCLEAR leukocytes , *IMMUNE response , *NEUTRALIZATION tests , *COVID-19 vaccines , *T cells - Abstract
• This study reports the safety and immunogenicity of the GLS-5310 DNA vaccine through 48 weeks. • First clinical application of the GeneDerm suction device for DNA vaccine delivery. • GLS-5310 was well tolerated and without vaccine-associated severe adverse effects. • T cell responses of ∼1200 site forming units/106 peripheral blood mononuclear cells were maintained through 48 weeks. • T cell responses were many-fold higher than all other vaccine platforms. • Antibody responses were induced in 95.5% and maintained through 48 weeks. The CoV2-001 phase I randomized trial evaluated the safety and immunogenicity of the GLS-5310 bi-cistronic DNA vaccine through 48 weeks of follow-up. A total of 45 vaccine-naïve participants were recruited between December 31, 2020, and March 30, 2021. GLS-5310, encoding for the SARS-CoV-2 spike and open reading frame 3a (ORF3a) proteins, was administered intradermally at 0.6 mg or 1.2 mg per dose, followed by application of the GeneDerm suction device as part of a two-dose regimen spaced either 8 or 12 weeks between vaccinations. GLS-5310 was well tolerated with no serious adverse events reported. Antibody and T cell responses were dose-independent. Anti-spike antibodies were induced in 95.5% of participants with an average geometric mean titer of ∼480 four weeks after vaccination and declined minimally through 48 weeks. Neutralizing antibodies were induced in 55.5% of participants with post-vaccination geometric mean titer of 28.4. T cell responses were induced in 97.8% of participants, averaging 716 site forming units/106 cells four weeks after vaccination, increasing to 1248 at week 24, and remaining greater than 1000 through 48 weeks. GLS-5310 administered with the GeneDerm suction device was well tolerated and induced high levels of binding antibodies and T-cell responses. Antibody responses were similar to other DNA vaccines, whereas T cell responses were many-fold greater than DNA and non-DNA vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
- Author
-
Song, Joon Young, Cheong, Hee Jin, Hyun, Hak Jun, Seo, Yu Bin, Lee, Jacob, Wie, Seong-Heon, Choi, Min Joo, Choi, Won Suk, Noh, Ji Yun, Yun, Jae Won, Yun, Jin Gu, and Kim, Woo Joo
- Subjects
- *
VACCINE safety , *PNEUMOCOCCAL vaccines , *INFLUENZA vaccines , *DRUG administration , *DISEASES in older people , *SEROCONVERSION - Abstract
Background Concomitant administration of influenza and pneumococcal vaccines could be an efficient strategy to increase vaccine uptake among older adults. Nevertheless, immune interference and safety issues have been a concern when more than one vaccines are administered at the same time. Methods Subjects aged ⩾60 years were randomized in a 1:1:1 ratio to receive MF59-adjuvanted trivalent inactivated influenza vaccine (MF59-aTIV) + 13-valent pneumococcal conjugate vaccine (PCV13) (Group 1), PCV13 alone (Group 2), or MF59-aTIV alone (Group 3). Hemagglutination inhibition (HI) and opsonophagocytic activity (OPA) assays were used to compare immunogenicity after single or concomitant vaccination. Results A total of 1149 subjects (Group 1, N = 373; Group 2, N = 394; Group 3, N = 382) were available for the assessment of immunogenicity and safety. All groups met immunogenicity criteria for the influenza vaccine in older adults with similar seroprotection rates, seroconversion rates, and geometric mean titer (GMT) fold-increases, irrespective of concomitant vaccination. For each pneumococcal serotype, OPA titers increased markedly after the PCV13 vaccination, irrespective of the concomitant influenza vaccination. After concomitant administration, the non-inferiority criteria of GMT ratios were met for all three influenza subtypes and 13 pneumococcal serotypes. No vaccine-related serious adverse events occurred. Conclusions Concomitant MF59-aTIV and PCV13 administration showed no interference with antibody response and showed good safety profiles. (Clinical Trial Number – NCT02215863 ). [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Viral shedding from diverse body fluids in a patient with severe fever with thrombocytopenia syndrome.
- Author
-
Jeong, Eun Ju, Song, Joon Young, Lim, Chae Seung, Lee, Ilseob, Park, Man-Seong, Choi, Min Joo, Jeon, Ji Ho, Kang, Seong Hui, Jung, Bo Kyeung, Yoon, Jin Gu, Hyun, Hak Jun, Noh, Ji Yun, Cheong, Hee Jin, and Kim, Woo Joo
- Subjects
- *
VIRAL shedding , *BODY fluids , *THROMBOCYTOPENIA , *TICK-borne diseases , *MULTIPLE organ failure , *BUNYAVIRUSES , *REVERSE transcriptase polymerase chain reaction - Abstract
Background Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne disease characterized by high fever, thrombocytopenia, leukopenia, and multiple organ failure and is caused by a novel bunyavirus. Human-to-human transmission has been reported previously, but the mode of transmission has not been clarified thoroughly. Study design We identified a case of a 73-year-old woman with SFTS and performed a semi-quantitative real-time reverse transcription PCR (real-time RT-PCR) assay on her blood, tracheal aspirate, gastric aspirate and urine to detect SFTS virus (SFTSV). Results During 7-day hospitalization, all the serum samples showed positive C t values lower than 35 in both the S and M segments, suggesting the presence of the SFTSV RNA. After initiation of plasma exchange, serum SFTSV load markedly decreased, but still remained positive. The SFTS viral RNA was also detected in other body fluids, including tracheal aspirate and gastric aspirate. Conclusion These results suggest that droplet transmission can occur through close contact with infected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.